X

Drug Profile

SNTX AXN

Alternative Names: SNTX-AXN

Latest Information Update: 07 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sensorium Therapeutics
Class Anxiolytics; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Anxiety disorders

Most Recent Events

10 Oct 2024 Preclinical trials in Anxiety disorders in USA (unspecified route), prior to October 2024
10 Oct 2024 Pharmacodynamics and adverse event data from preclinical trial in Anxiety disorders released by Sensorium Therapeutics
10 Oct 2024 Sensorium Therapeutics plans a phase I trial for Anxiety disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com